Management of Suspected Candidemia

Diagnostic Considerations

A negative Beta-D-Glucan (BDG) result does not exclude candidemia and should not be used alone to withhold or discontinue antifungal therapy in critically ill patients with high clinical suspicion 1, 2
BDG has a sensitivity of only 65-89% for candidemia at the 80 pg/mL threshold, meaning 11-35% of true cases will be missed 1, 3
The negative predictive value is approximately 85%, which still leaves a 15% false-negative rate 1
Blood cultures themselves only have 50-75% sensitivity for detecting Candida, so relying on either test alone is insufficient 1, 4

Continue or initiate empiric antifungal therapy if the patient has clinical signs of septic shock with risk factors for invasive candidiasis 2, 5
Consider mannan antigen and anti-mannan antibody testing, which can detect infection 6 days before blood cultures with 80% sensitivity and 85% specificity 1
Start or continue an echinocandin as first-line therapy, such as caspofungin 70 mg loading dose, then 50 mg daily, micafungin 100 mg daily, or anidulafungin 200 mg loading dose, then 100 mg daily 5

Only consider stopping antifungal therapy if all of the following are met: no clinical response improvement, all blood cultures remain negative after 4-5 days, repeat BDG testing remains negative, no subsequent evidence of invasive candidiasis develops, and clinical condition has alternative explanation 5
If any uncertainty remains, continue therapy for the full 2-week empiric course 5

Never use a single negative BDG to rule out candidemia in high-risk ICU patients—the false-negative rate is too high 2, 5
Do not delay antifungal therapy while awaiting repeat BDG or culture results in patients with septic shock and risk factors 2, 5
Avoid fluconazole as empiric therapy unless the patient has no recent azole exposure and local epidemiology confirms low azole resistance 5
Do not stop antifungals prematurely based solely on negative biomarkers if clinical suspicion remains high 2, 5